Latest Ratios: P/E Ratio -3.8x · EV/EBITDA 5.4x · ROE 578.1%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $3.2B | $2.6B | $3.0B | $2.9B | $2.3B | $9.9B | $7.4B | $10.5B | $6.5B | $7.3B | $5.0B |
| Enterprise Value | $23.0B | $22.5B | $23.6B | $24.4B | $22.5B | $32.0B | $30.7B | $33.2B | $30.0B | $32.0B | $34.3B |
| P/E Ratio → | -3.83 | 16.16 | — | — | — | — | — | — | — | 2.42 | — |
| P/S Ratio | 0.28 | 0.25 | 0.31 | 0.33 | 0.28 | 1.17 | 0.92 | 1.22 | 0.77 | 0.84 | 0.52 |
| P/B Ratio | 8.44 | 6.93 | — | — | 8.74 | — | 12.20 | 9.27 | 2.30 | 1.23 | 1.55 |
| P/FCF | 1.73 | 2.60 | 2.35 | 3.85 | — | 8.67 | 9.21 | 8.61 | 5.10 | 3.74 | 2.81 |
| P/OCF | 2.26 | 1.86 | 1.86 | 2.84 | — | 6.95 | 6.65 | 7.02 | 4.31 | 3.19 | 2.42 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.19 | 2.45 | 2.78 | 2.77 | 3.79 | 3.83 | 3.86 | 3.59 | 3.67 | 3.55 |
| EV / EBITDA | 5.41 | 6.63 | 8.39 | 10.94 | 12.16 | 15.97 | 12.28 | 17.73 | 69.07 | 10.82 | 14.93 |
| EV / EBIT | 10.55 | 11.41 | 12.65 | 15.03 | 15.15 | 18.72 | 23.38 | 24.73 | 60.09 | 57.72 | 28.50 |
| EV / FCF | — | 22.42 | 18.74 | 32.06 | — | 27.98 | 38.28 | 27.14 | 23.73 | 16.39 | 19.12 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 70.7% | 70.7% | 71.1% | 70.8% | 70.9% | 71.6% | 72.0% | 72.7% | 71.9% | 70.8% | 73.4% |
| Operating Margin | 21.3% | 21.3% | 16.1% | 11.0% | 5.6% | 5.3% | 8.4% | -2.4% | -28.4% | 1.2% | -5.9% |
| Net Profit Margin | 1.5% | 1.5% | -0.5% | -6.8% | -2.8% | -11.2% | -7.0% | -20.7% | -49.5% | 27.6% | -24.9% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 578.1% | 578.1% | — | -665.2% | -199.1% | -332.0% | -64.2% | -90.3% | -94.7% | 52.2% | -51.9% |
| ROA | 0.6% | 0.6% | -0.2% | -2.2% | -0.8% | -3.1% | -1.7% | -5.8% | -12.8% | 5.9% | -5.2% |
| ROIC | 8.1% | 8.1% | 5.6% | 3.5% | 1.6% | 1.5% | 2.1% | -0.6% | -6.3% | 0.2% | -1.2% |
| ROCE | 10.4% | 10.4% | 7.2% | 4.3% | 2.0% | 1.8% | 2.5% | -0.8% | -8.4% | 0.3% | -1.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 56.36 | 56.36 | — | — | 79.87 | — | 39.55 | 22.79 | 8.63 | 4.28 | 9.16 |
| Debt / EBITDA | 6.25 | 6.25 | 7.76 | 10.05 | 11.24 | 11.32 | 9.57 | 13.83 | 55.87 | 8.60 | 12.98 |
| Net Debt / Equity | — | 52.84 | — | — | 77.70 | — | 38.55 | 19.94 | 8.38 | 4.16 | 8.99 |
| Net Debt / EBITDA | 5.86 | 5.86 | 7.34 | 9.63 | 10.93 | 11.02 | 9.32 | 12.10 | 54.22 | 8.35 | 12.74 |
| Debt / FCF | — | 19.83 | 16.38 | 28.21 | — | 19.31 | 29.08 | 18.52 | 18.63 | 12.65 | 16.32 |
| Interest Coverage | 1.23 | 1.23 | 1.35 | 1.22 | 1.01 | 1.20 | 0.86 | 0.83 | 0.30 | 0.30 | 0.66 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.47 | 1.47 | 0.86 | 1.30 | 1.08 | 1.08 | 1.09 | 1.12 | 0.19 | 1.11 | 1.41 |
| Quick Ratio | 1.08 | 1.08 | 0.62 | 0.94 | 0.80 | 0.89 | 0.86 | 0.94 | -0.06 | 0.87 | 1.11 |
| Cash Ratio | 0.32 | 0.32 | 0.17 | 0.22 | 0.14 | 0.11 | 0.12 | 0.52 | 0.19 | 0.17 | 0.15 |
| Asset Turnover | — | 0.39 | 0.36 | 0.32 | 0.32 | 0.29 | 0.26 | 0.25 | 0.31 | 0.23 | 0.22 |
| Inventory Turnover | 1.85 | 1.85 | 1.74 | 1.66 | 2.17 | 2.41 | 2.06 | 2.12 | 2.52 | 2.43 | 2.43 |
| Days Sales Outstanding | — | 83.44 | 81.15 | 83.28 | 80.42 | 76.82 | 71.71 | 78.04 | 81.23 | 89.12 | 94.97 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | 6.2% | — | — | — | — | — | — | — | 41.3% | — |
| FCF Yield | 57.7% | 38.5% | 42.5% | 26.0% | — | 11.5% | 10.9% | 11.6% | 19.6% | 26.7% | 35.6% |
| Buyback Yield | 0.0% | 0.0% | 0.9% | 0.0% | 0.0% | 0.0% | 0.0% | 0.4% | 0.2% | 0.1% | 0.2% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.9% | 0.0% | 0.0% | 0.0% | 0.0% | 0.4% | 0.2% | 0.1% | 0.2% |
| Shares Outstanding | — | $375M | $368M | $365M | $362M | $359M | $355M | $352M | $350M | $352M | $347M |
Includes 30+ ratios · 30 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BHC stock.
Bausch Health Companies Inc.'s current P/E ratio is -3.8x. The historical average is 25.5x.
Bausch Health Companies Inc.'s current EV/EBITDA is 5.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 20.6x.
Bausch Health Companies Inc.'s return on equity (ROE) is 578.1%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -17.6%.
Based on historical data, Bausch Health Companies Inc. is trading at a P/E of -3.8x. Compare with industry peers and growth rates for a complete picture.
Bausch Health Companies Inc. has 70.7% gross margin and 21.3% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
Bausch Health Companies Inc.'s Debt/EBITDA ratio is 6.3x, indicating high leverage. A ratio above 4x may signal elevated financial risk.
Key Metrics
Top Statement Risk
Negative equity and heavy leverage
Metrics are mathematically derived from official filings.
Low Multiples Mask Leverage-Driven Equity Risk
Based on reported figures, BHC trades at 19.02x trailing earnings and 6.64x EV/EBITDA, multiples that look modest in isolation but sit against a stockholders' deficit that makes the P/B of 8.15x a distorted reference point.
The trailing P/E of 19.02 rests on earnings that swung from a $1.4B loss to a $436.0M profit within the last few quarters, so it reflects a volatile base rather than a stable earnings run-rate. The forward P/E of 1.71 implies the market expects a sharp earnings rebound, which warrants further investigation before treating it as a signal of value. EV/EBITDA of 6.64x against peer Prestige Consumer Healthcare at 8.86x suggests BHC is priced at a discount, which may reflect the market pricing in its debt load of roughly $20.7B.
Operating Gains Fail to Reach Net Earnings
As reported in financial statements, BHC's operating margin reached 33.4% in 2026Q3, yet net margin was only 14.8% and was negative in several earlier quarters, indicating that interest and other non-operating charges absorb much of the operating gain.
The gap between operating margin and net margin points to a capital structure where financing costs consume a large share of operating profit. Gross margin swung between 57.6% and 99.0% across the ten quarters, so the spread appears driven by reporting variability rather than stable pricing power. Given this, net margin is a more conservative measure of earning power than operating margin, though quarterly volatility limits confidence in any single period.
ROIC Recovering From a Thin Base
According to recent quarterly ratios, BHC's ROIC rose from 1.1% in 2025Q1 to 8.6% in 2026Q3, a notable improvement, though ROE remains undefined because of the stockholders' deficit.
The ROIC recovery appears to be driven primarily by margin expansion rather than improved capital efficiency, since asset turnover remains low at around 0.10 to 0.12. With ROE unusable due to negative book equity, ROIC is the more meaningful return measure here, but its latest reading still sits well below a typical cost of capital for a leveraged issuer. Investors should monitor whether the 2026Q3 level holds across subsequent periods.
Debt Service Strained Despite Coverage Swings
Based on BHC's reported figures, debt-to-EBITDA moved from roughly 25 to 36 times in earlier periods to 16.35 times in 2026Q3, while interest coverage swung from negative in 2026Q1 to 2.50 in the latest quarter.
Debt levels relative to EBITDA remain elevated by any conventional standard, and the improvement in 2026Q3 coincides with a sharp rebound in operating income rather than a visible reduction in debt. Interest coverage of 2.50 is adequate but leaves limited room for earnings shortfalls given the scale of obligations. Refinancing exposure and covenant terms are not disclosed in the supplied data, so the degree of near-term risk cannot be fully assessed from these figures.
Goodwill and Lumpy Cash Flow Overstate Strength
As reported in financial statements, goodwill of $9.8B exceeds the entire stockholders' deficit, and free cash flow margin ranged from 3.3% to 36.5%, so headline asset and cash metrics may overstate sustainable value and cash generation.
Goodwill accounts for roughly 38% of total assets, meaning the balance sheet's apparent scale depends heavily on acquisition accounting that may not reflect realizable value. The wide swing in free cash flow margin suggests working capital timing and one-off items are driving quarterly results more than a durable run-rate. Analysts should treat the 2026Q2 free cash flow margin of 36.5% as an outlier pending confirmation in later periods rather than as evidence of structural improvement.